U.S. markets closed


XETRA - XETRA Delayed Price. Currency in EUR
21.80+0.60 (+2.83%)
At close: 05:36PM CET


Lilienthalstraße 3a
Schönefeld 12529
49 30 897 30 86 70

IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees76

Key Executives

NameTitlePayExercisedYear Born
Mr. Patrick BrenskeMD & Member of Management BoardN/AN/AN/A
Mr. Attila StraussMD & Member of Management BoardN/AN/A1985
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements. In addition, it provides pharmaceuticals in the areas of HIV/AIDS, neurology, oncology, and rheumatology diseases. Further, the company develops, manufactures, and distributes diagnostic tests under the HAEMATO brand, and cosmetics under the brand M1 SELECT, as well as supplies third party-products. It serves clinics, pharmacies, wholesalers, and medical test centers. HAEMATO AG was founded in 1993 and is based in Schönefeld, Germany.

Corporate Governance

HAEMATO AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.